This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Lucy Chard
3 Jul 2023

Updated: Samsung Biologics to manufacture Pfizer's biosimilars products

Samsung Biologics agrees to use their biocampus Plant 4 for the manufacture of a line of products from Pfizer. 

In a big step to strengthen partnerships and expand manufacturing capabilities, Samsung Biologics have entered into an agreement with Pfizer to take over the long-term commercial manufacturing of Pfizer’s portfolio. 

In March 2023 the two companies signed an agreement stating that Samsung Biologics would start manufacturing one of Pfizer’s products, now this new deal encompasses multiple products from Pfizer. The product portfolio is extensive, including in the fields of inflammation, immunology, and oncology. 

Samsung Biologics will use their most recently operational manufacturing plant, Plant 4, to manufacture the Pfizer product portfolio. This was the first plant developed as a bio campus, which will be closely followed by the in-progress Plant 5, and then through to Plant 8. The partnership will serve to massively increase Pfizer’s capacity for large-scale manufacturing of their biosimilars products. 

“We are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe,” commented John Rim, President and CEO of Samsung Biologics. “This new meaningful partnership comes just as our Plant 4 is fully completed early this month as we had previously committed and are on the move for future expansion into our second campus in order to provide our clients with even more flexible and advanced manufacturing technology.” 

“Pfizer is excited to continue our strategic partnership with Samsung Biologics Ltd. that aims to enable greater access to medicines for more patients across the world,” stated Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer. “This commitment is a reflection of Pfizer’s trust in the Korean Pharmaceutical industry to address emerging health challenges.” 

“Our collaboration with Samsung Biologics will have the potential to significantly improve the lives of patients globally,” added Dong-Wook Oh, Pfizer Korea Country Manager.


Only July 3, Samsung Biologics and Pfizer signed two mega deals for the long-term manufacturing of Pfizer's biosimilar portfolio totaling USD $897m. The products will be manufactured at Samsung Biologics' newest Plant 4 manufacturing facility in South Korea with the world's largest manufacturing capacity at a single site, boasting 240,000 litres. The deals are expected to last through to 2029. 

Source: Samsung Biologics. Company news. Samsung Biologics and Pfizer announce strategic collaboration for long-term manufacturing of biosimilars portfolio. [Date accessed 13.06.2023]. 

Mentioned Companies
Samsung Biologics Co., Ltd.
View company profile
Lucy Chard
Digital Editor - Pharma

Related News